Faculty Profiles - KURIMOTO Keisuke

Papers - KURIMOTO Keisuke

Division display 21 - 35 of about 35 ／ All the affair displays >>

Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue. International journal

Yuki Sunagawa, Suguru Yamada, Fuminori Sonohara, Keisuke Kurimoto, Nobutake Tanaka, Yunosuke Suzuki, Yoshikuni Inokawa, Hideki Takami, Masamichi Hayashi, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera

Scientific reports Vol. 11 ( 1 ) page： 6016 - 6016 2021.3

Language：English Publishing type：Research paper (scientific journal)

Circular RNA (circRNA) is a type of non-coding RNA known to affect cancer-related micro RNAs and various transcription factors. circRNA has promise as a cancer-related biomarker because its circular structure affords high stability. We found using high-throughput sequencing that seven candidate circRNAs (hsa_circ_0041150, hsa_circ_0025624, hsa_circ_0001020, hsa_circ_0028129, hsa_circ_0008558, hsa_circ_0036683, hsa_circ_0058087) were downregulated in HCC. The expression of these circRNAs was examined by quantitative PCR in 233 sets of HCC and matched background normal liver tissues, and correlations between candidate circRNA expression and prognosis were evaluated. The results of quantitative PCR showed that expression of hsa_circ_0041150, hsa_circ_0001020 and hsa_circ_0008558 was significantly lower in HCC than in background normal liver tissues. Kaplan-Meier analysis revealed that low expression of hsa_circ_0001020, hsa_circ_0036683, and hsa_circ_0058087 was associated with poor recurrence-free (RFS) and overall survival (OS) in HCC. Additionally, multivariate analysis revealed that low hsa_circ_0036683 expression was a significant prognostic factor, independent from other clinicopathological features, for inferior RFS and OS. There was no significant association between the expression of these circRNAs and hepatitis B/C status or cirrhosis. This study therefore identified circRNAs as potential prognostic markers for patients who undergo curative surgery for HCC and highlighted hsa_circ_0036683 as the most useful biomarker.

DOI： 10.1038/s41598-021-85237-y

Web of Science

Scopus

PubMed

Fuminori Sonohara, Suguru Yamada, Keisuke Kurimoto, Yoshikuni Inokawa, Hideki Takami, Masamichi Hayashi, Dai Shimizu, Norifumi Hattori, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Tsutomu Fujii, Yasuhiro Kodera

Pancreas Vol. 50 ( 1 ) page： 37 - 46 2021.1

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVES: In this study, we retrospectively assessed the feasibility and prognostic efficacy of perioperative chemo(radio)therapy for pancreatic cancer (PC) patients according to age. METHODS: A total of 556 consecutive patients who underwent curative-intent pancreatectomy for PC between 2000 and 2018 were enrolled. RESULTS: Of the 556 patients who underwent resection, 95 (17%) were elderly (age, ≥75 years). Postoperative complications did not significantly differ between the 2 age groups, and postoperative prognoses were also similar (recurrence-free survival [RFS], P = 0.68; overall survival [OS], P = 0.28). In this cohort, 103 patients (19%) underwent preoperative chemo(radio)therapy, and 417 (77%) underwent postoperative chemotherapy. Perioperative therapy was found to be significantly beneficial for younger patients (preoperative therapy: RFS, P = 0.006; OS, P < 0.001; postoperative therapy: RFS, P < 0.001; OS, P < 0.001). Conversely, no significant survival benefit of perioperative therapy was found for the elderly (preoperative therapy: RFS, P = 0.28; OS, P = 0.44; postoperative therapy: RFS, P = 0.77; OS, P = 0.08). CONCLUSIONS: This study demonstrated that, although perioperative therapy is feasible for selected elderly patients with PC, this approach might not be as beneficial as it is for younger PC patients.

DOI： 10.1097/MPA.0000000000001712

Web of Science

Scopus

PubMed

Difference Between Educational Law and the Present Status of Continuing Education of High School-Aged Patients with Cancer

Ozawa, M; Maeda, N; Mori, M; Kurimoto, K; Tsuchiya, M; Horibe, K

PEDIATRIC BLOOD & CANCER Vol. 67 2020.12

ゲノムワイドアプローチによる肝細胞癌関連circRNAの探索

砂川祐輝, 山田豪, 園原史訓, 栗本景介, 猪川祥邦, 高見秀樹, 林真路, 中山吾郎, 小池聖彦, 小寺泰弘

日本消化器外科学会総会 Vol. 75回 page： P219 - 4 2020.12

膵臓化学療法

砂川祐輝, 山田豪, 山中雅也, 鈴木雄之典, 中川暢彦, 加藤吉康, 田中伸孟, 栗本景介, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 311 - 311 2020.11

大腸癌初回肝転移手術後の早期再発予測因子の検討

林真路, 山田豪, 高見秀樹, 猪川祥邦, 園原史訓, 砂川祐輝, 田中伸孟, 栗本景介, 加藤吉康, 中川暢彦, 鈴木雄之典, 神田光郎, 田中千恵, 小林大介, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 120回 page： DP - 4 2020.8

膵頸部癌における臨床病理学的特徴

栗本景介, 山田豪, 鈴木雄之典, 中川暢彦, 加藤吉康, 田中伸孟, 砂川祐輝, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 120回 page： SF - 3 2020.8

膵頭部癌における周術期輸血の長期予後に対する影響

田中伸孟, 山田豪, 栗本景介, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 中山吾郎, 小池聖彦, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 120回 page： SF - 3 2020.8

膵頭十二指腸切除術施行膵癌患者における周術期メインおよびリパクレオン投与の安全性と有用性

中川暢彦, 山田豪, 多代充, 栗本景介, 園原史訓, 清水大, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 神田光郎, 田中千恵, 小林大介, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 120回 page： DP - 5 2020.8

膵癌に対する膵頭十二指腸切除術の分子生物学的なsurgical marginの評価

砂川祐輝, 山田豪, 林真路, 高見秀樹, 猪川祥邦, 園原史訓, 栗本景介, 田中伸孟, 加藤吉康, 中川暢彦, 鈴木雄之典, 神田光郎, 田中千恵, 小林大介, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 120回 page： SF - 2 2020.8

進行膵癌におけるオリゴメタスタシス症例の検討

林真路, 山田豪, 高見秀樹, 園原史訓, 猪川祥邦, 田中伸孟, 加藤吉康, 中川暢彦, 栗本景介, 鈴木雄之典, 山中雅也, 小寺泰弘

膵臓 Vol. 35 ( 3 ) page： A304 - A304 2020.7

胃原発mixed adenoneuroendocrine carcinomaの1例

荘加道太, 清水大, 栗本景介, 園原史訓, 猪川祥邦, 高見秀樹, 服部憲史, 林真路, 神田光郎, 田中千恵, 小林大介, 山田豪, 中山吾郎, 小池聖彦, 小寺泰弘

日本消化器病学会東海支部例会プログラム抄録集 Vol. 131回 page： 59 - 59 2019.11

日本のAYA世代のがん対策の方向性を読み解く Reviewed

栗本景介, 堀部敬三, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 神田光郎, 小林大介, 田中千恵, 山田豪, 中山吾郎, 小池聖彦, 清水千佳子, 高橋義行, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 57回 page： P166 - 5 2019.10

Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy. Reviewed

Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y

Journal of translational medicine Vol. 17 ( 1 ) page： 1 2019.1

PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma Reviewed

Keisuke Kurimoto, Masamichi Hayashi, Rafael Guerrero-Preston, Masahiko Koike, Mitsuro Kanda, Sho Hirabayashi, Hiroshi Tanabe, Nao Takano, Naoki Iwata, Yukiko Niwa, Hideki Takami, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Goro Nakayama, Hiroyuki Sugimoto, Tsutomu Fujii, Michitaka Fujiwara, Yasuhiro Kodera

EPIGENETICS Vol. 12 ( 10 ) page： 865 - 874 2017

Language：English Publishing type：Research paper (scientific journal) Publisher：TAYLOR & FRANCIS INC

Therapeutic strategies for esophageal cancer largely depend on histopathological assessment. To select appropriate treatments of individual patients, we examined the background molecular characteristics of tumor malignancy and sensitivity to multidisciplinary therapy. Seventy-eight surgically-resected esophageal squamous cell carcinoma (ESCC) cases during 2001-2013 were examined. PAX5, a novel gene methylation marker in ESCC, was evaluated in the specimens, as methylation of this gene was identified as an extremely tumor-specific event in squamous cell carcinogenesis of head and neck. PAX5 methylation status was evaluated by quantitative MSP (QMSP) assays. Mean QMSP value was 15.7 (0-136.3) in ESCCs and 0.3 (0-8.6) in adjacent normal tissues (P < 0.001). The 78 cases were divided into high QMSP value (high QMSP, n D 26) and low QMSP value (low QMSP, n D 52). High QMSP cases were significantly associated with downregulated PAX5 expression (P D 0.040), and showed significantly poor recurrencefree survival [Hazard Ratio (HR) D 2.84; P D 0.005; 95% Confidence Interval (CI): 1.39-5.81] and overall survival (HR D 3.23; P D 0.002; 95% CI: 1.52-7.01) in multivariable analyses with histopathological factors. PAX5-knockdown cells exhibited significantly increased cell proliferation and cisplatin resistance. PAX5 gene methylation can predict poor survival outcomes and cisplatin sensitivity in ESCCs and could be a useful diagnostic tool for cancer therapy selection.

DOI： 10.1080/15592294.2017.1365207

Web of Science

Scopus

PubMed

　 PREV - NEXT 　

<KURIMOTO Keisuke>

Papers - KURIMOTO Keisuke